Cystone in kidney stones
- Conditions
- Health Condition 1: null- urolithiasis
- Registration Number
- CTRI/2012/01/002350
- Lead Sponsor
- The Himalaya Drug
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 60
?Subject with Urolithiasis as disgnosed by clinically as well as ultrasonographically with calculi measuring more than 5 mm.
?Hematologic and Biochemical parameters within normal limits.
? Willing to sign inform consent document
?Those with serious cardiovascular, cerebrovascular, respiratory, liver or renal disease or any other disorder.
?The subjects not to have used any drugs, for at least 1 week prior to the study.
?Subjects with a strong history of food or drug allergy of any kind.
?Subjects not to have been on weight reducing diets within 3 months prior to the start of the study.
?No other drugs (including aspirin) to be ingested during the course of the study.
?Patients unwilling to provide informed consent or abide by the requirements of the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method symptomatic relief from clinical symptoms of urolithiasis and reduction in the stone size by ultrasonographyTimepoint: 3 months
- Secondary Outcome Measures
Name Time Method To assess the safety profile of Cystone Extract route tablet in Urolithiasis and overall compliance to the drug treatment. <br/ ><br>Timepoint: At monthly intervals for the period of 3 months